|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Stanford University |
|---|---|
| Information provided by: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00568425 |
Purpose
The purpose of this study is show that intensity-modulated radiotherapy (IMRT), as compared with conventional radiotherapy, improves the precision of tumor targeting and reduces the acute and late effects of radiation toxicity when used to treat anal cancer. Results from this work will provide a basis for incorporating the use of IMRT to treat anal cancer in future treatment protocols.
| Condition |
|---|
|
Anal Cancer |
| Study Type: | Observational |
| Official Title: | Quality of Life and Functional Outcomes After Combined Modality Therapy for Anal Cancer: A Comparison of Conventional Versus Intensity-Modulated Radiation Therapy (ANAL0002) |
| Estimated Enrollment: | 30 |
| Study Start Date: | September 2005 |
The objectives of this study are three-fold. First, we would like to learn and compare the doses of radiation received by the tumor and the normal tissues in anal cancer patients treated with IMRT, and in those treated with conventional radiotherapy.
Second, we wish to compare the acute effects of radiation treatment in both groups of patients. Our third objective is to evaluate the late effects of radiation treatment in both groups of patients. The first two objectives will be studied using a retrospective analysis of patients with anal cancer treated at Stanford University Medical Center. The third objective will require these patients to complete and return three quality of life questionnaires.
Eligibility| Ages Eligible for Study: | 30 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:Histologically confirmed diagnosis of squamous cell carcinoma of the anus. Must be able to provide informed consent.
 Exclusion Criteria:History of new malignancy since the time of treatment for anal cancer. Non-English speaking.
Contacts and Locations| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Moe Jalali 650-724-4023 moej@stanford.edu | |
| Contact: Cancer Clinical Trials Office (650) 498-7061 | |
| Principal Investigator: Mark Lane Welton | |
| Sub-Investigator: Albert Koong | |
| Sub-Investigator: Brett Cox | |
| Principal Investigator: | Mark Lane Welton | Stanford University |
More Information
| Study ID Numbers: | SU-11062007-812, 96405, ANAL0002, NCT00568425 |
| Study First Received: | December 4, 2007 |
| Last Updated: | November 19, 2008 |
| ClinicalTrials.gov Identifier: | NCT00568425 History of Changes |
| Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
|
Digestive System Neoplasms Rectal Neoplasms Gastrointestinal Diseases Rectal Neoplasm Quality of Life Intestinal Diseases Anal Cancer |
Rectal Diseases Intestinal Neoplasms Digestive System Diseases Rectal Cancer Gastrointestinal Neoplasms Anus Neoplasms Colorectal Neoplasms |
|
Digestive System Neoplasms Rectal Neoplasms Gastrointestinal Diseases Intestinal Diseases Rectal Diseases Intestinal Neoplasms Neoplasms |
Neoplasms by Site Digestive System Diseases Gastrointestinal Neoplasms Anus Neoplasms Anus Diseases Colorectal Neoplasms |
